Mouse IL-17RB Alexa Fluor® 405-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: IL-17RB

The Interleukin 17 (IL-17) family of cytokines, comprising six members (IL-17, IL-17B through IL-17F), are structurally related proteins with a conserved cysteine-knot structure. These proinflammatory cytokines can induce local cytokine production and are involved in the regulation of the immune response. The cognate receptors activated by some of these cytokines have been identified (1, 2). Interleukin-17B Receptor (IL-17 RB), also known as IL-17 Rh1, IL-17E R and EVI27, represents the second receptor of the IL-17 family cytokines to be recognized (2‑4). Mouse IL-17 RB cDNA encodes a 499 amino acid (aa) type I membrane protein with a putative 17 aa signal peptide, a 269 aa extracellular domain, a 21 aa transmembrane domain and a 192 aa cytoplasmic tail. As a result of alternative splicing, a secreted variant of IL-17 RB also exists (5). Human and mouse IL‑17 RB share 76% aa sequence identity. IL-17 RB is approximately 20% identical to the human and mouse IL‑17 R. However, the receptors share many conserved cysteine residues within their extracellular domains as well as additional conserved elements within their cytoplasmic domains. At least three additional type I transmembrane receptors with homology to IL‑17 R, including IL-17 RL (IL-17 RC), IL-17 RD, and IL-17 RE, have been reported (2, 6). By Northern blot analysis, mouse IL-17 RB is highly expressed in liver and testes and is expressed at lower levels in kidney and lung. It is also expressed in some hematopoietic cell lines, including selected T cell, B cell, and myeloid cell lines (2‑4). The expression of IL-17 RB is significantly upregulated under inflammatory conditions (7). IL-17 RB binds strongly to IL-17E and weakly to IL-17B. It does not bind IL-17 or IL-17F. Activation of IL-17 RB by its ligands results in the activation of nuclear factor kappa-B (2‑4).

Product Datasheets

Product Specific Notices

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Related Research Areas

• Group 2 ILCs
• IL-17 Family
• Natural Killer T (NKT) Cells
• Th2 Cells
• Th9 Cells